Additions & Corrections

A Compilation of Two Decades of Mutagenicity Test Results with the Ames *Salmonella typhimurium* and L5178Y Mouse Lymphoma Cell Mutation Assays [Volume 19, Number 5, May 2006, pp 627–644] H. E. SEIFRIED,* R. M. SEIFRIED, J. J. CLARKE, T. B. JUNGHANS, AND R. H. C. SAN

A review of the mouse lymphoma studies revealed that in early studies with handwritten data entries, doses were reported in μL/mL rather than the more commonly reported μg/mL. The *Salmonella* data are correctly reported in μg/mL. The following tables contain the appropriate corrections discovered during the aforementioned review. Table A lists the compounds that should be reported as μL/mL for the dose ranges and the lowest effective dose. The Supporting Information file "Table 4 Supporting Information—Mouse Lymphoma Test Data" has been modified to reflect all of these changes and can be used as is. Table B contains amended rows where data were incorrectly incorporated. These rows supplant those in Table 1 in the original paper.

Table A

chemical tested by volume, listed by weight	dose range	chemical tested by volume, listed by weight	dose range
acetaldehyde	0.07–0.8 μL/mL	hexamethyldisilazane	4.2–9 μL/mL
acetaldehyde oxime	0.1–22 μL/mL	isoamyl nitrite	0.15–0.7 μL/mL
acetic anhydride	0.04–0.3 μL/mL	isoamyl nitrite	0.3–1.8 μL/mL
acrylonitrile	0.034–0.15 μL/mL	isoamyl nitrite (retest)	0.03–2.2 μL/mL
allyl alcohol	0.002–11 μL/mL	isobutyl nitrite	0.0025–0.22 μL/mL
allyltrimethylsilane	0.01–0.37 μL/mL	isobutyl nitrite	0.1–1 μL/mL
n-amyl-nitrite	0.11–0.36 μL/mL	isobutyl nitrite (retest)	0.03–0.7 μL/mL
n-amyl nitrite	0.04–0.44 μL/mL	isoeugenol	0.007–0.1 μL/mL
p-anisaldehyde	0.09–0.9 μL/mL	KIPA (oxazolidinone)	10–87 μL/mL
benzonitrile	0.39–1.21 μL/mL	lead naphthenate	0.01–0.25 μL/mL
Biobor JF [2,2′-(1-methyltrimethylene-dioxy)-bis(4-methyl-1,3,2-dioxaborinane)]	0.9–20 μL/mL	linoleic acid	0.005–0.07 μL/mL
borane-THF copmplex	7.3–15 μL/mL	linolelaidic acid	0.005–0.05 μL/mL
1-bromo-4-fluorobenzene	0.001–.1 μL/mL	linolenic acid	0.005–0.04 μL/mL
butanal oxime	0.08–3 μL/mL	manganese naphthenate	0.02–0.1 μL/mL
2-butanone oxime	1.7–7.5 μL/mL	methyldichlorosilane	0.18–0.5 μL/mL
n-butyl nitrite	0.16–0.87 μL/mL	methylene chloride	1–8.7 μL/mL
sec-butyl nitrite	0.04–1.4 μL/mL	methyl isocyanate	0.35–5.2 nL/mL
calcium naphthenate	0.005–0.5 μL/mL	2-methyl-2-(methylthio) propionaldoxime (aldicarb oxime)	1.1–1.7 μL/mL
chavicol	0.00065–0.14 μL/mL	methyl trifluoro-methanesulfonate	0.5–3.1 μL/mL
chloromethyldimethyl vinyl silane	0.054–0.2 μL/mL	nitromethane	4.6–22 μL/mL
p-chloro-α,α,α-trifluorotoluene	0.01–0.07 μL/mL	*N*-nitroso-*N*-methyl-*p*- aminobenzoic acid, 2-ethylhexyl ester A	0.001–0.2 μL/mL
chlorotrimethylsilane	0.02–0.12 μL/mL	*N*-nitroso-*N*-methyl-*p*- aminobenzoic acid, 2-ethylhexyl ester B	0.41–1 μL/mL
trans-cinnamaldehyde (3-phenyl-2-propenal)	0.001–0.049 μL/mL	octamethylcyclotetra-siloxane	0.005–1 μL/mL
cinnamyl cinnamate (3-phenyl-2-propenyl-1-ol, 2-amino-benzoate)	0.02–0.7 μL/mL	octamethyltrisiloxane	0.01–1 μL/mL
cobalt naphthenate	0.01–0.22 μL/mL	*cis*-2-pentenenitrile	0.004–1 μL/mL
copper naphthenate	0.01–0.1 μL/mL	3-phenylpropanol	0.1–1 μL/mL
cyclohexanone	0.1–7.5 μL/mL	polyvinylchloride latex	0.3–4.4 μL/mL
cis-1,4-dichloro-2-butene	0.5–12 μL/mL	1-propanethiol	0.011–0.61 μL/mL
trans-1,4-dichloro- 2-butene	0.004–6 μL/mL	propenoic acid	0.11–2.2 μL/mL
dichloromethylvinyl silane	0.044–1 μL/mL	propylene sulfide	0.02–0.2 μL/mL
2,3-dichloropropylene	0.0036–0.03 μL/mL	*n*-propyl nitrite	0.2–2.5 μL/mL
dimethyldichloro-silane	0.14–2 μL/mL	styrene	0.05–0.18 μL/mL
N,*N*-dimethyl-*p*-toluidine	0.005–0.31 μL/mL	α-terpineol	0.14–0.65 μL/mL
dimethylvinyl-chloride	0.06–0.4 μL/mL	thionyl chloride	0.024–0.31 μL/mL
dipropylene glycol	29–60 μL/mL	thiophene	0.05–1.8 μL/mL
1,3-divinyltetra-methyldisialazane	0.1–2.2 μL/mL	*o*-tolunitrile	0.02–0.61 μL/mL
dodecenylsuccinic anhydride	0.017–0.31 μL/mL	trichlorofluoromethane (freon 11)	0.5–30 μL/mL
n-dodecylmercaptan	0.001–0.087 μL/mL	trichlorosilane	0.02–0.19 μL/mL
ecteinascidin (ET-743)	0.00025–0.05 ng/mL	triethoxyvinyl silane	0.1–0.9 μL/mL
ethylene glycol diacrylate	0.6–65 nL/mL	triethylgermanium chloride	0.01–0.15 μL/mL
ethylene glycol dimethacrylate	0.19–1.7 μL/mL	trimethylolpropane triacrylate	0.0003–0.035 μL/mL
ethylene glycol dimethacrylate	1–100 μL/mL	trimethylolpropane triacrylate	0.0001–0.0009 μL/mL
ethylene glycol dimethacrylate	0.09–1.4 μL/mL	trimethylolpropane trimethacrylate	0.021–0.2 μL/mL
ethylene sulfide	0.025–0.1 μL/mL	vinyl acetate	1.8–5 μL/mL
2-fluorophenol	0.0001–0.6 μL/mL	*p*-vinyl guaiacol	0.009–0.04 μL/mL
2-fluorophenol	0.001–0.1 μL/mL	zinc naphthenate	0.0033–0.05 μL/mL
hexamethyldisilazane	2–5 μL/mL		

Table B. Table 1 Amended for Errata or Omissions

		Ames *Salmonella* evaluation			mouse lymphoma evaluation: nonactivated		mouse lymphoma evaluation: S9-activated			
chemical name	CAS no.	evaluation	dose (μg/plate)	strain	old eval/ LED	new eval/ LED	old eval/ LED	new eval/ LED	dose (μg/mL) or μL/mL	ref
4-aminostyrene	1520-21-4	P/333	33–3333	TA98, 100, 1535	N	N	N	N	100–300	
azacytosine arabinoside	65886-71-7	negative	10–10000		I	I	I	I	1.0–100	
bilberry extract (myrtocyan)	84082-34-8	negative	100–10000		N	N	N	N	2.0–15	
bisphenol S	80-09-1	negative	0.1–3333		P/250	N	P/250	N	100–300	
blue green algae (Cell Tech)		negative	100–10000		N	N	N	N	30–100	
borane-THF complex					P/15	P/13	P/11	P/11	7.3–15 μL/mL	
1,3-butadiene	106-99-0	negative	0.1–10 min		N	N	N	N	3–10 min	
deferoxamine mesylate	138-14-7				P/0.25	P/0.5	P/0.25	P/0.5	0.1–1.5 mM	
p-*N*,*N*-dimethyl- aminophenethanol	50438-75-0	P/333	333–10000	TA98, 1535, 1538	N	N	P/100	I	100–2900	
ecteinascidin (ET-743)	114899-77-3	P/0.33	0.033–30	TA98	P/0.5	P/0.5	P/10	P/10	0.00025–0.05 ng/mL	
ethylene glycol diacrylate	2274-11-5	negative	33–6667		P/1.4	E	P/36	E	0.6–65 nL/mL	
4,4-bis(4-hydroxyphenyl) valeric acid	126-00-1	negative	100–10000		P/50	P/100	P/2300	P/2500	50–2500	
isoamyl nitrite	110-46-3	P/1000	100–6667	TA1535	P/0.6	E	P/0.2	P/0.3	0.15–0.7 μL/mL	*63*
methyl isocyanate	624-83-9	negative	10–1000		P/0.7	P/0.79	N	N	0.35–5.2 nL/mL	
4′,5,7-trihydroxy- flavone (apigenin)	520-36-5	negative	33–10000		P/1.5	P/1.5	P/15	P/35	1.5–100	*20*, *41*
tropolone	533-75-5	negative	1.0–333		P/3.9	P/7.8	P/31	N	4–250	

TX800011S

10.1021/tx800011s
Published on Web 01/25/2008

Development of Liquid Chromatograpy Electrospray Ionization Tandem Mass Spectrometry Methods for Analysis of DNA Adducts of Formaldehyde and Their Application to Rats Treated with *N*-Nitrosodimethylamine or 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone. [Volume 20, Number 8, August 2007, pp 1141–1148] MINGYAO WANG, GUANG CHENG, PETER W. VILLALTA, AND STEPHEN S. HECHT*

Through an oversight, we did not mention that the data in the last four columns of Table 6 were from a previous publication (*1*) and were included here for comparison. This should have been noted as a footnote in the table. The section in Experimental Procedures on "Treatment of Rats with NDMA or NNK" should have noted that the experiment was that described in ref *1*. The section on "Analysis of DNA for POB−DNA Adducts" should have said, "These were previously determined and are included for comparison."

Reference

(1) Lao, Y., Villalta, P. W., Sturla, S. J., Wang, M., and Hecht, S. S. (2006) Quantitation of pyridyloxobutyl DNA adducts of tobacco-specific nitrosamines in rat tissue DNA by high performance liquid chromatography-electrospray ionization-tandem mass spectrometry. *Chem. Res. Toxicol. 19*, 674–682.

TX700407K

10.1021/tx700407k
Published on Web 01/05/2008

Identification of the Highly Reactive Cysteine 151 in the Chemopreventive Agent-Sensor Keap1 Protein is Method-Dependent [Volume 20, Number 12, December 2007, pp 1878–1884]

AIMEE L. EGGLER, YAN LUO, RICHARD B. VAN BREEMEN, AND ANDREW D. MESECAR*

Because of an error during production, Table 3 was published incorrectly. The correct version of Table 3 is as follows.

Table 3. Detection of Peptides after Keap1 Treatment by the "Solution" or "Membrane" Method[a]

	solution method			membrane method		
	BIA[b]	IA[b]	NM[b]	BIA	IA	NM
Cys-151	1,2,3	1,2	2,3	0	3	0
Cys-226	1,2,3	1,2	3	1,2,3	1,2,3	0
Cys-257	1,2,3	0	2,3	1,2,3	0	0
Cys-273	1,2,3	1,2	2	1,2	1,3	0
Cys-288	1,2,3	1,2	2	1,2,3	1,2,3	0
Cys-297	1,2,3	2	2	1,2	2,3	0
Cys-319	1,2,3	1,2	3	1,2	1	0
Cys-434	1,2,3	1,2	3	1,2	1,2,3	0
Cys-613	1,2,3	1,2	3	1,2	1,3	0
Cys-23	2,3	1,2	3	1,2	1,3	0
Cys-38	2,3	1,2	3	1,2	1,3	0
Cys-13	2	1,2	3	1,2	1,3	0
Cys-14	2	1,2	3	1,2	1,3	0
Cys-77	2	1,2	3	1,2,3	1,2,3	0
Cys-241	0	1,2	3	1,2	1,2,3	0
Cys-249	0	1,2	3	1,2	2,3	0
Cys-368	0	1,2	3	1,3	1,2,3	0
Cys-489	0	1,2	3	1,2,3	1,2,3	0
Cys-518	0	1,2	3	1,2	1,2,3	0
Cys-622	0	1,2	3	1,2	1,2,3	0
Cys-624	0	1,2	3	1,2	1,2,3	0
Cys-171	0	2	3	0	3	0
Cys-196	0	2	3	0	3	0
Cys-395	0	1,2	0	0	0	0
Cys-406	0	1,2	0	0	0	0
Cys-513	0	1,2	3	0	1,2,3	0
Cys-583	0	2	3	0	2,3	0

[a] A 5:1 molar ratio of BIA/Keap1 was used in the experiments, which were performed in triplicate. Modified peptides were detected using LC−MS/MS with a LTQ-FT ICR MS. [b] Indicates in which experiments the BIA-modified peptide, the IA-modified peptide, and the unmodified peptide, respectively, were found.

TX800015C

10.1021/tx800015c
Published on Web 02/18/2008